Arrivent Biopharma Inc (AVBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2023 | 03-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -33,739 | -12,172 | -36,906 | -51,606 |
| Accounts payable and accrued liabilities | 3,314 | -380 | N/A | N/A |
| Other Working Capital | 7,893 | -4,875 | -7,149 | -3,941 |
| Other Operating Activity | -2,955 | 546 | 424 | 42,960 |
| Operating Cash Flow | $-25,487 | $-16,881 | $-43,631 | $-12,587 |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | -25,000 | N/A | N/A | N/A |
| Other Investing Activity | 0 | 0 | 0 | -40,000 |
| Investing Cash Flow | $-25,000 | $N/A | $0 | $-40,000 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 30 | 26 | N/A | N/A |
| Other Financing Activity | 44,919 | 44,943 | 169,723 | 89,867 |
| Financing Cash Flow | $44,949 | $44,969 | $169,723 | $89,867 |
| Beginning Cash Position | 163,372 | 163,372 | 37,280 | 0 |
| End Cash Position | 157,834 | 191,460 | 163,372 | 37,280 |
| Net Cash Flow | $-5,538 | $28,088 | $126,092 | $37,280 |
| Free Cash Flow | ||||
| Operating Cash Flow | -25,487 | -16,881 | -43,631 | -12,587 |
| Free Cash Flow | -25,487 | -16,881 | -43,631 | -12,587 |